Insights into Renal Cell Carcinoma (RCC)

Current treatment practice regarding therapy of advanced renal cell carcinoma (RCC), recently introduced and upcoming agents

PA, MD, VA – December 15, 2020

Faculty Chair

Daniel M. Geynisman, MD

Fox Chase Cancer Center, Philadelphia, PA, USA

Example Report

Start discovering the insights

View Report


  • A roundtable discussion, moderated by an Axess Oncology Network physician, focusing on treatment of advanced RCC was held on December 15, 2020, in a virtual setting
  • Disease state and data presentations were developed by Daniel M. Geynisman, MD, a medical expert from Fox Chase Cancer Center, Philadelphia
  • Insights on the following therapies were obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs


  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 11 community oncologists from practices in Pennsylvania, Maryland, Virginia, and the District of Columbia

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.